Lysophosphatidic acid (LPA) - A perspective marker in ovarian cancer

Tumor Biology

Volumn 32, Issue 2, 2011, Pages 311-316

  Sedláková, Iva ^a   Vávrová, Jaroslava ^a   Tošner, Jindřich ^a   Hanousek, Ladislav ^b  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b Hospitals of the Pardubice Region   (Czech Republic)

Author keywords

Diagnostics; Lysophosphatidic acid; Marker; Ovarian carcinoma

Indexed keywords

LYSOPHOSPHATIDIC ACID; TUMOR MARKER; LYSOPHOSPHOLIPID;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER GRADING; CANCER STAGING; CAPILLARY ELECTROPHORESIS; CLINICAL INDICATOR; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; LIPID BLOOD LEVEL; OVARY CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HUMANS; LYSOPHOSPHOLIPIDS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 79953775007     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-010-0123-8     Document Type: Article

References (20)

1. Schwartz PE, Taylor KJ. Is early detection of ovarian cancer possible? An Med. 1995;27:519-28.
2. Mills GB, May C, McGill M, et al. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res. 1988;48:1066-71. (Pubitemid 18075508)
3. Fishman DA, Bozorgi K. The scientific basis of early detection of epithelial ovarian cancer: The National Ovarian Cancer Early Detection Program [NOCEDP]. Cancer Treat Res. 2002;107:3-28.
4. Fang X, Schummer M, Mao M, et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta. 2002;23:57-64.
5. So J, Navari J, Wang FO, Fishman DA. Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. Gynec Oncol. 2004;95:314-22. (Pubitemid 39445866)
6. Xiao YJ, Schwartz B, Washington M, Kennedy A, Webster K, Belinson J, et al. Electrospray ionization spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant versus nonmalignant ascitic fluids. Anal Biochem. 2001;290:302-13. (Pubitemid 32217542)
7. Hu YL, Tee MK, Goetzl EJ, Auersperg N, Mills GB, Ferrara N, et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst. 2006;93:762-8.
8. Lee Z, Swaby FR, Liang Y, Yu S, Liu S, Lu KH, et al. Lysophophatidic Acid Is a Major Regulator of Growth-Regulated Oncogene in Ovarian Cancer. Cancer Res. 2006;66:2740-8.
9. Fujita T, Miyamoto S, Onoyama I, et al. Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophopsphatidic acid in the development of human ovarian cancer. Cancer Lett. 2003;192:161-9. (Pubitemid 36369270)
10. Wang P, Wu X, Chen W, Liu J, Wang X. The lysophosphatidic acid [LPA] receptors their expression and significance in epithelial ovarian neoplasms. Gynec Oncol. 2007;104:714-20. (Pubitemid 46240254)
11. Eder AM, Sasagawa T, Mao M, Aoki J, Mills GB. Constitutive and lysophosphatidic acid [LPA]-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res. 2000;6:2482-91.
12. Ozols RF, Rubin SC, Thomas G, Robboy S. Asdf. In: Hoskins WJ, Perez CA, Zouny RC, editors. Epithelial ovarian cancer. Principles and practisse of gynecologic oncology. Philadelphia: Lippincott-Raven; 1997. p. 958.
13. WHO. WHO Handbook for reporting results of cancer treatment. Geneva: WHO; 1979.
14. Sutphen R, Xu Y, Wilbanks D, Fiorica J, Grendys Jr EC, La Polla JP, et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidem. 2004;13:1185-91. (Pubitemid 38917907)
15. Okita M, Gaudette DC, Mills GB, Holub BJ. Elevated levels and altered fatty acid composition of plasma lysophosphatidylicholine in ovarian cancer patients. Int J Cancer. 1997;71:31-4. (Pubitemid 27158406)
16. Yan Xu, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998;280:719-23. (Pubitemid 28405297)
17. Sedláková I, Vávrová J, Tošner J, Hanousek L. Lysophosphatidic acid in ovarian cancer patients. ?eská gynekologie. 2006;71:312-7. (Pubitemid 44252138)
18. Baker DL, Morrison P, Miller B, Riely CA, Tolley B, Westermann AM, et al. Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA. 2002;287:3081-2.
19. Pozlep B, Meleh M, Kobal B, et al. Use of lysophosphatidic acid in the management of benign and malignant ovarian tumors. Eur J Gynaecol Oncol. 2007;28:394-9. (Pubitemid 47535553)
20. So J, Wang F, Navari J, Schreher J, Fishman DA. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynec Oncol. 2005;97:870-8. (Pubitemid 40824659)